Saturday, 12 December 2009

UK Telegraph - NICE Propose to Restrict Key IBD Treatments to One Year on Grounds of Cost

Yet more justification, if any were needed that the UK NHS needs to seriously look into widespread use of Low Dose Naltrexone (LDN) as a low cost treatment for Crohn's Disease, Ulcerative Colitis and the any other conditions it has been used successfully to reat including other auto-immune disease, cancers, autism and HIV/AIDs.

At £12,500 per patient per year for Infliximab versus £300 per year for Low Dose Naltrexone, it is the proverbial 'no-brainer' for the NHS to do whatever it takes to convince consultants and GPs that LDN is a suitable drug choice for IBD.

The government and public bodies need to cease dithering on this and take action now so that IBD sufferers need not suffer unnecessarily.


  1. Well said Bob, who is running this country that they cannot work that out for themselves??
    It's a sad reflection on todays'society.......

  2. Bob,

    Quite correct!

    By the way, please correct the above "(Typically 1/50)" to read "Typically less than 1/10)".